Novo Nordisk in Talks to Sell Wegovy and Ozempic via Hims & Hers
Novo Nordisk is in talks to sell its Wegovy and Ozempic weight-loss drugs via Hims & Hers’ telehealth platform, potentially ending their legal feud and expanding direct-to-consumer distribution. News of the partnership sent Hims & Hers shares up about 44% in premarket trading and nudged Novo Nordisk’s stock marginally higher, with an announcement possible as early as Monday.
1. Partnership Talks
Novo Nordisk is exploring an agreement to distribute its FDA-approved GLP-1 weight-loss drugs Wegovy and Ozempic through Hims & Hers’ telehealth platform. The deal could be announced as early as Monday and aims to leverage Hims & Hers’ direct-to-consumer model to boost patient access and prescription volume.
2. Market Reaction
Premarket trading saw Hims & Hers shares surge approximately 44% on optimism over expanded distribution, while Novo Nordisk’s stock edged slightly higher. Investors view the potential partnership as a low-cost channel to accelerate sales of high-margin obesity treatments.
3. History of Feud
Discussions between the two companies had broken down last year after Hims & Hers continued selling lower-cost compounded semaglutide despite supply normalization. The telehealth provider also abandoned plans to offer a compounded version of Novo Nordisk’s oral Wegovy pill following regulatory scrutiny.